Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
ZAI LAB LTD (ZLAB)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$22.60-0.88%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for ZLAB yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Improve cash from operations to reduce cash burn | Cash flow is improving, with operating cash burn down to $12 million in Q1 2026. | Broken | cash burn worsens beyond -$12 million next year | Cash from operations: $-63.406M FY2026-Q2; GAAP. Published target: cash burn no worse than -$12 million. Reported actuals cannot certify a consensus target without an explicit period and accounting-basis binding. Aug 6, 2026-63,406,000 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative growth business, with a long-term thesis tied to oncology and immunology pipeline progress and commercial launches. The thesis is in a watch state: stated priorities are advancing, but recent financial performance is weak and the business remains loss-making.
The valuation is expensive versus peers, with a premium and an expectations gap linked to pipeline optionality, or the potential value of future opportunities. Model confidence is low, and the evidence does not show that the full combination of expensive valuation, weak results, and turbulence is already reflected in expectations.
Near term, revenue may remain under pressure: it declined year over year in both reported 2026 quarters, even as second-quarter revenue rose sequentially. Operating loss widened from the first quarter to the second, while management continues to advance the pipeline and work toward product growth in 2027. The next results carry meaningful execution risk, given erratic earnings surprises and the risk of a guidance cut.
The multi-year view hinges on whether product sales stabilize and return to growth in 2027, and whether pipeline and China launch progress translate into stronger commercial results. Near term, a guidance cut would be a negative signal; continued strength from healthcare bellwethers could support the sector backdrop, while weaker jobs data could raise recession concerns.
ZLAB has pipeline and sector support, but year-over-year revenue declines, widening operating losses, and an expensive peer valuation leave the long-term thesis dependent on clearer commercial progress. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Maintain stable leadership to execute strategy |
| A supporting condition in ZAI LAB LTD's published investment case. The stated target is no further major leadership departures. |
| Under Pressure |
| additional senior leadership departures occur |
1 leadership shake-up event (Jun 2026) vs 0 allowed June 2026 headline reports leadership shake-up; subsequent Q3 2026 earnings and financing news show no additional executive departures. Nov 5, 2026Last status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Reduce operating losses and improve operating income over time | A primary condition in ZAI LAB LTD's published investment case. The stated target is operating loss less negative than -$69.4 million. | Broken | operating loss worsens beyond -$69.4 million next year | Operating income: $-62.978M FY2026-Q3; GAAP. Published target: operating loss less negative than -$69.4 million. Reported actuals cannot certify a consensus target without an explicit period and accounting-basis binding. Nov 5, 2026-62,978,000 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Grow total revenue to at least $460 million in 2026 | Zai Lab aims to grow revenue to about $460 million in 2026. | Intact | revenue falls below $460 million in FY26 | Revenue: $108.208M FY2026-Q3; GAAP. Published target: >= $460 million. Annual target cannot be compared with a quarterly or TTM observation. Nov 5, 2026108,208,000 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-1.69 → $-2.14 · observed estimates
$0.57B → $0.51B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-1.69 | $565,534,707 | 7 / 11 |
| 2026-07-25 | $-1.75 | $595,574,470 | 10 / 16 |
| 2026-07-26 | $-1.75 | $595,574,470 | 10 / 16 |
| 2026-07-27 | $-1.69 | $565,534,707 | 7 / 11 |
| 2026-07-28 | $-1.70 | $564,330,278 | 7 / 11 |
| 2026-07-29 | $-1.70 | $564,330,278 | 7 / 11 |
| 2026-07-30 | $-1.76 | $594,595,880 | 10 / 16 |
| 2026-07-31 | $-1.64 | $563,426,693 | 7 / 11 |
| 2026-08-01 | $-1.64 | $563,426,693 | 7 / 11 |
| 2026-08-02 | $-1.76 | $594,595,880 | 10 / 16 |
| 2026-08-03 | $-1.76 | $594,595,880 | 10 / 16 |
| 2026-08-04 | $-1.64 | $563,426,693 | 7 / 11 |
| 2026-08-05 | $-1.64 | $563,426,693 | 7 / 11 |
| 2026-08-06 | $-1.64 | $563,426,693 | 7 / 11 |
| 2026-08-08 | $-1.64 | $563,426,693 | 7 / 11 |
| 2026-08-09 | $-1.64 | $563,426,693 | 7 / 11 |
| 2026-08-10 | $-1.64 | $563,426,693 | 7 / 11 |
| 2026-08-12 | $-2.06 | $572,560,850 | 10 / 16 |
| 2026-08-13 | $-1.64 | $563,426,693 | 7 / 11 |
| 2026-08-14 | $-1.64 | $563,426,693 | 7 / 11 |
| 2026-08-15 | $-1.64 | $563,426,693 | 7 / 11 |
| 2026-08-16 | $-1.64 | $563,426,693 | 7 / 11 |
| 2026-08-17 | $-1.64 | $563,426,693 | 7 / 11 |
| 2026-08-18 | $-1.64 | $563,426,693 | 7 / 11 |
| 2026-08-19 | $-1.64 | $563,426,693 | 7 / 11 |
| 2026-08-20 | $-2.06 | $522,742,477 | 7 / 12 |
| 2026-08-21 | $-2.06 | $522,742,477 | 7 / 12 |
| 2026-08-22 | $-2.06 | $522,742,477 | 7 / 12 |
| 2026-08-23 | $-2.06 | $522,742,477 | 7 / 12 |
| 2026-08-24 | $-2.06 | $522,742,477 | 7 / 12 |
| 2026-08-25 | $-2.09 | $520,689,443 | 7 / 12 |
| 2026-08-26 | $-2.09 | $520,689,443 | 7 / 12 |
| 2026-08-27 | $-2.09 | $520,689,443 | 7 / 12 |
| 2026-08-28 | $-2.09 | $520,689,443 | 7 / 12 |
| 2026-08-29 | $-2.13 | $517,407,453 | 7 / 12 |
| 2026-08-30 | $-2.13 | $517,407,453 | 7 / 12 |
| 2026-08-31 | $-2.13 | $517,407,453 | 7 / 12 |
| 2026-09-01 | $-2.13 | $517,407,453 | 7 / 12 |
| 2026-09-02 | $-2.13 | $517,407,453 | 7 / 12 |
| 2026-09-03 | $-2.13 | $517,407,453 | 7 / 12 |
| 2026-09-04 | $-2.13 | $517,407,453 | 7 / 12 |
| 2026-09-05 | $-2.13 | $517,407,453 | 7 / 12 |
| 2026-09-06 | $-2.13 | $517,407,453 | 7 / 11 |
| 2026-09-07 | $-2.13 | $517,407,453 | 7 / 11 |
| 2026-09-08 | $-2.13 | $517,407,453 | 7 / 11 |
| 2026-09-09 | $-2.13 | $517,407,453 | 6 / 11 |
| 2026-09-10 | $-2.13 | $517,407,453 | 6 / 11 |
| 2026-09-11 | $-2.13 | $517,407,453 | 6 / 11 |
| 2026-09-12 | $-2.13 | $517,407,453 | 6 / 11 |
| 2026-09-13 | $-2.13 | $517,407,453 | 6 / 11 |
| 2026-09-14 | $-2.13 | $517,407,453 | 6 / 11 |
| 2026-09-15 | $-2.13 | $517,407,453 | 6 / 11 |
| 2026-09-16 | $-2.13 | $517,407,453 | 6 / 11 |
| 2026-09-17 | $-2.13 | $517,407,453 | 6 / 11 |
| 2026-09-18 | $-2.13 | $517,407,453 | 6 / 11 |
| 2026-09-19 | $-2.13 | $517,407,453 | 6 / 11 |
| 2026-09-20 | $-2.15 | $515,669,564 | 6 / 11 |
| 2026-09-21 | $-2.15 | $515,669,564 | 6 / 11 |
| 2026-09-22 | $-2.15 | $515,669,564 | 6 / 11 |
| 2026-09-23 | $-2.15 | $515,669,564 | 6 / 11 |
| 2026-09-24 | $-2.15 | $515,669,564 | 6 / 11 |
| 2026-09-25 | $-2.15 | $515,669,564 | 6 / 11 |
| 2026-09-26 | $-2.15 | $515,669,564 | 6 / 11 |
| 2026-09-27 | $-2.15 | $515,669,564 | 6 / 11 |
| 2026-09-28 | $-2.15 | $515,669,564 | 6 / 11 |
| 2026-09-29 | $-2.15 | $515,669,564 | 6 / 11 |
| 2026-09-30 | $-2.15 | $515,669,564 | 6 / 11 |
| 2026-10-01 | $-2.15 | $515,669,564 | 6 / 11 |
| 2026-10-02 | $-2.15 | $515,669,564 | 6 / 11 |
| 2026-10-03 | $-2.15 | $515,669,564 | 6 / 11 |
| 2026-10-04 | $-2.15 | $515,669,564 | 6 / 11 |
| 2026-10-05 | $-2.15 | $515,669,564 | 6 / 11 |
| 2026-10-06 | $-2.15 | $515,669,564 | 6 / 11 |
| 2026-10-07 | $-2.15 | $515,669,564 | 6 / 11 |
| 2026-10-08 | $-2.15 | $515,669,564 | 6 / 11 |
| 2026-10-09 | $-2.15 | $515,669,564 | 6 / 11 |
| 2026-10-10 | $-2.15 | $515,669,564 | 6 / 11 |
| 2026-10-11 | $-2.15 | $515,669,564 | 6 / 11 |
| 2026-10-12 | $-2.15 | $515,669,564 | 6 / 11 |
| 2026-10-13 | $-2.15 | $515,669,564 | 6 / 11 |
| 2026-10-14 | $-2.15 | $515,669,564 | 6 / 11 |
| 2026-10-15 | $-2.15 | $515,669,564 | 6 / 11 |
| 2026-10-16 | $-2.15 | $515,669,564 | 6 / 11 |
| 2026-10-17 | $-2.15 | $515,669,564 | 6 / 11 |
| 2026-10-18 | $-2.15 | $515,669,564 | 6 / 11 |
| 2026-10-19 | $-2.15 | $515,669,564 | 6 / 11 |
| 2026-10-20 | $-2.15 | $515,669,564 | 6 / 11 |
| 2026-10-21 | $-2.15 | $515,669,564 | 6 / 11 |
| 2026-10-22 | $-2.15 | $515,669,564 | 6 / 11 |
| 2026-10-23 | $-2.15 | $515,669,564 | 6 / 11 |
| 2026-10-24 | $-2.15 | $515,669,564 | 6 / 11 |
| 2026-10-25 | $-2.15 | $515,669,564 | 6 / 11 |
| 2026-10-26 | $-2.15 | $515,669,564 | 6 / 11 |
| 2026-10-27 | $-2.15 | $515,669,564 | 6 / 11 |
| 2026-10-28 | $-2.15 | $515,669,564 | 6 / 10 |
| 2026-10-29 | $-2.15 | $515,669,564 | 6 / 10 |
| 2026-10-30 | $-2.15 | $515,669,564 | 6 / 10 |
| 2026-10-31 | $-2.15 | $515,669,564 | 6 / 10 |
| 2026-11-01 | $-2.15 | $515,669,564 | 6 / 10 |
| 2026-11-02 | $-2.15 | $515,669,564 | 6 / 10 |
| 2026-11-03 | $-2.15 | $515,669,564 | 6 / 10 |
| 2026-11-04 | $-2.14 | $514,529,094 | 6 / 10 |
| 2026-11-05 | $-2.14 | $514,529,094 | 6 / 10 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 10 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.